Fresh analysis reveals that individuals who discontinue new slimming jabs like Wegovy and Mounjaro may regain lost weight at a significantly accelerated pace than those who stop traditional lifestyle plans.
Research printed in a leading medical journal shows that while obese individuals often shed substantial amounts of their body weight while undergoing treatment, the weight comes back at an estimated rate of 0.8 kg per month once they quit.
"Individuals using these treatments should be cognizant of the potential of quick rebound weight gain when the medication ends," warns lead investigator Dr. Susan Jebb.
Such speed of recovery means a reversion to original weight within about 18 months.
Comparing Approaches
The study, which examined 37 of studies involving thousands of participants, contrasted the outcomes of GLP-1 agonists with conventional dieting.
Researchers note that individuals who shed pounds through dieting typically experience a slower creep back—approximately 100 grams monthly—post-intervention.
The Reason for the Rapid Rebound
Doctors propose the mechanism of the injections is key to understanding the amplified regain.
These medications mimic a body's own chemical called glucagon-like peptide-1, which controls hunger.
"Sustained high doses of the hormone concentrations several times higher than the body's typical production may cause the body to generate a reduced amount of its endogenous GLP-1, and could lessen sensitivity to its actions," noted Dr. Adam Collins, a nutrition researcher.
"Stopping of this medication means appetite is no longer kept in check, making overeating far more likely."
A Chronic Condition?
Health authorities suggest the injections for people with weight-linked health risks, alongside recommended lifestyle changes.
Many experts argue that, due to the likelihood of weight regain, the therapy is often ongoing.
This perspective is echoed by pharmaceutical companies, who say that the results "highlight the persistent character of obesity," akin to managing diseases like hypertension.
Patient Accounts
Users who have stopped the jabs report a sudden return of cravings.
"It felt as if a trigger activating and you become ravenous," said a patient.
This challenge is exacerbated if users have not adopted sustainable lifestyle or habit modifications during therapy.
Growing Adoption
Figures indicate that millions of adults in the UK have tried weight-loss jabs in the past year, with interest continuing to grow.
- Use is more common among females than men.
- The 40s and 50s demographic shows the highest level of interest.
- Many access the medications through private healthcare rather than public health services.
In conclusion, researchers emphasize that while GLP-1 drugs are potent tools for shedding pounds, they are not a magic solution and lasting health benefits relies on combined behavioural support.
